Transcatheter Arterial Chemoembolization Combined With Sorafenib for Unresectable Hepatocellular Carcinoma
NCT01833299
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
120
Enrollment
OTHER
Sponsor class
Conditions
Hepatocellular Carcinoma
Face Cancer
Interventions
PROCEDURE:
TACE-Sorafenib group
PROCEDURE:
TACE
Sponsor
Sun Yat-sen University